Draft:Joshua M. Hare
From Wikipedia, the free encyclopedia
I am the subject of the article Draft:Joshua M. Hare and am submitting it for review in accordance with Wikipedia guidelines. I will avoid direct editing of the article after submission and will use the talk page for any suggested changes.
 | This is a draft article. It is a work in progress open to editing by anyone. Please ensure core content policies are met before publishing it as a live Wikipedia article. Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL Last edited by Frietjes (talk | contribs) 4 days ago. (Update)
This draft has been submitted and is currently awaiting review. |
Johns Hopkins University (MD)
Joshua M. Hare | |
|---|---|
| Born | Joshua Michael Hare |
| Education | University of Pennsylvania (BA) Johns Hopkins University (MD) |
| Known for | Clinical trials of stem cell therapy for cardiovascular disease and aging-related conditions |
| Scientific career | |
| Fields | Cardiology, regenerative medicine |
| Institutions | University of Miami Johns Hopkins University |
 | Review waiting, please be patient.
This may take 2 months or more, since drafts are reviewed in no specific order. There are 4,369 pending submissions waiting for review.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Reviewer tools
|
 | The following Wikipedia contributor may be personally or professionally connected to the subject of this page. Relevant policies and guidelines may include conflict of interest, autobiography, and neutral point of view.
|
Joshua Michael Hare is an American cardiologist and biomedical researcher known for his work in regenerative medicine and stem cell therapy. He is a professor at the University of Miami Miller School of Medicine and founding director of the Interdisciplinary Stem Cell Institute.
His research has focused on the development of cell-based therapies for cardiovascular disease, aging-related frailty, and neurodegenerative conditions. His work has been covered in independent sources including The New York Times and Nature, which have reported on advances in stem cell therapies and described the field as reaching a turning point.[1][2][3]
Early life and education
Hare received a Bachelor of Arts from the University of Pennsylvania and a Doctor of Medicine from the Johns Hopkins University School of Medicine. He completed residency training in internal medicine at Johns Hopkins Hospital and fellowships in cardiovascular disease and research at Harvard-affiliated institutions, including Brigham and Women's Hospital.[4]
Academic career
Hare began his academic career at Johns Hopkins University, where he held faculty appointments in medicine and biomedical engineering and served in leadership roles in cardiovascular medicine and the Institute for Cell Engineering.
In 2007, he joined the University of Miami Miller School of Medicine, where he served as chief of the cardiovascular division from 2007 to 2009 and became founding director of the Interdisciplinary Stem Cell Institute. He also directs the Donald Soffer Endowed Program in Regenerative Medicine.[4]
Research
Cardiovascular biology
Early in his career, Hare conducted research on nitric oxide signaling and its role in myocardial function and heart failure.
Cardiac regeneration and cell therapy
Hare has led or contributed to clinical trials investigating mesenchymal stem cell therapies for heart disease. The POSEIDON trial, published in JAMA, was among the first randomized studies to compare allogeneic and autologous stem cell therapies in patients with ischemic cardiomyopathy, demonstrating the safety and feasibility of allogeneic (“off-the-shelf”) therapy.[5]
A subsequent randomized trial (TAC-HFT), also published in JAMA, reported reductions in scar size and improvements in cardiac structure following cell therapy.[6]
These studies contributed to the development of allogeneic mesenchymal stem cell therapy as a scalable approach to cardiac regeneration.
Aging and frailty
Hare's work has also focused on stem cell therapies for aging-related frailty. In 2026, results from a clinical trial were featured in Nature, which reported improvements in physical function in older adults and described the findings as among the strongest evidence to date for a treatment targeting biological aging.[2]
Neurodegenerative disease
Stem cell therapies relevant to neurodegenerative diseases have been discussed in Nature Medicine, which reported that the field is reaching a "turning point" and noted emerging applications in conditions including Alzheimer's disease.[3]
Media coverage
Hare has been quoted in coverage of stem cell research in The New York Times, which has reported on the progress and challenges of the field.[1]
Publications and impact
Hare has authored numerous peer-reviewed publications in journals including Circulation, Journal of the American College of Cardiology, Proceedings of the National Academy of Sciences, and JAMA. His work has been widely cited in the scientific literature, with an H-index exceeding 100.[4]
Honors and affiliations
Hare is a Fellow of the American College of Cardiology and the American Heart Association.